The Quebec Court of Appeal has confirmed that is it unconstitutional for the PMPRB to compel companies to provide information from 3rd party agreements.

On December 23, 2021, the Minister of Health, Jean-Yves Duclos announced a delay in the coming-into-force of the Regulations Amending the Patented Medicines Regulations by six months.

On December 17, 2021, the PMPRB posted an update that read, “The Board has decided not to proceed with the changes that were proposed in the July 15, 2021 Notice and Comment.

Read about the two major announcements have been made in the last couple of weeks pertaining to the PMPRB.

CADTH has announced the establishment of a Special Advisory Panel to design a potential pan-Canadian formulary.

The PMPRB has updated their website to state the coming-into-force of the amended Patented Medicines Regulations has been further delayed until January 1, 2022.

Twitter was abuzz with a letter from Christopher MacLeod, Canadian Cystic Fibrosis Treatment Society to the President of the Treasury Board, House of Commons & the Auditor General Canada with a request to investigate PMPRB for “targeting & de-legitimizing the Patient Voice”.

Quebec will be moving to a biosimilars only program by April 12, 2022.

COVID-19 is a humanitarian crisis that’s now having a growing impact on Canadian healthcare. Popular opinion seems to be that “the new normal”, whatever that looks like, will not arrive before the second half of 2021.

After several weeks of consultation, the PMPRB has made their decision regarding the definition of Gap Medicines and the compliance timelines for Grandfathered and Gap Medicines.